Spots Global Cancer Trial Database for MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Official Title: Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV)

Study ID: NCT05269771

Conditions

Polycythemia Vera

Interventions

Ruxolitinib

Study Description

Brief Summary: The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Detailed Description: The requesting Treating Physician must submit a request for access to drug (often referred to as Compassionate Use) to Novartis which will review and approve by the medical team experienced with the drug and indication.